University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Medicine (RMH)
  • Medicine (RMH) - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Medicine (RMH)
  • Medicine (RMH) - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Current and emerging antiviral treatments for hepatitis C infection

    Thumbnail
    Citations
    Scopus
    Web of Science
    Altmetric
    43
    36
    Author
    Doyle, JS; Aspinall, E; Liew, D; Thompson, AJ; Hellard, ME
    Date
    2013-04-01
    Source Title
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    Publisher
    WILEY
    University of Melbourne Author/s
    Liew, Danny; Thompson, Alexander; Hellard, Margaret
    Affiliation
    Medicine - Royal Melbourne Hospital
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Doyle, J. S., Aspinall, E., Liew, D., Thompson, A. J. & Hellard, M. E. (2013). Current and emerging antiviral treatments for hepatitis C infection. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 75 (4), pp.931-943. https://doi.org/10.1111/j.1365-2125.2012.04419.x.
    Access Status
    Access this item via the Open Access location
    URI
    http://hdl.handle.net/11343/33201
    DOI
    10.1111/j.1365-2125.2012.04419.x
    Open Access at PMC
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612710
    Description

    C1 - Journal Articles Refereed

    Abstract
    Newly licensed direct acting antivirals for hepatitis C virus HCV are able to cure up to 75% of patients chronically infected with genotype-1 infection, which is the predominant HCV strain in Europe and North America. Emerging antiviral therapies promise further increases in virological response, as well as improved tolerability, reduced duration of therapy, and will potentially eliminate the need for interferon use. This review highlights the main therapeutic agents used in current standard of care, including telaprevir and boceprevir. It goes on to evaluate the mechanisms of emerging drugs, their stage of development and response rates seen in research to date. Finally, it projects into the not too distant future to consider treatment strategies involving combinations of agents and interferon-free therapies, and in which patients they might prove most successful.
    Keywords
    Infectious Diseases; Clinical Pharmacology and Therapeutics; Preventive Medicine

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [53039]
    • Medicine (RMH) - Research Publications [782]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors